Therapy Detail

Therapy Name poly ICLC
Therapy Description

Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373).


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Poly ICLC Hiltonol Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02126579 Phase Ib/II poly ICLC Long peptide vaccine 7 Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Recruiting
NCT02334735 Phase II poly ICLC Melan-A/MART-1 peptide vaccine NY-ESO-1 peptide vaccine A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence Recruiting
NCT03068832 Phase I poly ICLC Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors Not yet recruiting
NCT02425306 Phase Ib/II Cyclophosphamide 6MHP vaccine poly ICLC Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma Terminated
NCT02423863 Phase II poly ICLC In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol Recruiting
NCT01188096 Phase II poly ICLC A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas Active, not recruiting
NCT02413827 Phase Ib/II Nivolumab + Varlilumab DEC-205-NY-ESO-1 fusion protein vaccine poly ICLC A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma Terminated
NCT02166905 Phase Ib/II poly ICLC DEC-205-NY-ESO-1 fusion protein vaccine Epacadostat DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Recruiting
NCT01532960 Phase I poly ICLC Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41) Terminated
NCT02332889 Phase Ib/II Decitabine poly ICLC Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs Terminated
NCT02358187 Phase II poly ICLC A Vaccine Trial for Low Grade Gliomas Recruiting
NCT02510950 Phase I Sargramostim poly ICLC Temozolomide Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma Terminated
NCT02078648 Phase Ib/II SL-701 poly ICLC Bevacizumab Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Completed
NCT02427581 Phase I poly ICLC Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Suspended
NCT01130077 Phase I poly ICLC A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas Recruiting
NCT02754362 Phase II poly ICLC Bevacizumab A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma Active, not recruiting